Greffex’s platform has numerous applications for delivering vaccines, gene therapies, cancer treatments, and transplantation therapies.
Greffex Universal Vaccine Application
We have an advanced, universal vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean adenoviral vectors
• Pipeline of over 12 vaccines including SARS-CoV-2, H5N1, Universal Flu, MERS-CoV, Anthrax, Ebola , tetrava- lent Dengue, Zika and Lyme’s disease
Greffex’s Competitive Advantage
When you start with a better foundation, the end result is enhanced. Greffex’s foundation is a fully-deleted, helper virus-independent adenoviral vector used to introduce genetic sequences for any chosen array of pro- teins. This technology is patented. No one else has such a clean vector (100% clean) with such a large payload capacity (33kb).